Get started
Author

Мишугин Сергей Владимирович

Observed names: S V Mishugin, S. Mishugin, S. V. MISHUGIN, S. V. Mishugin, S.V. Mishugin Mishugin, SV Mishugin, Sergej V. Mishugin, Sergey Mishugin, Sergey V. Mishugin, Sergey Vladimirovich Mishugin, Мишугин С. В., Мишугин С.В., С В Мишугин, С. В. Мишугин
ORCID: 0000-0002-6751-2399
Observed ORCIDs: 0000-0002-6751-2399, 0009-0007-0907-4937, 0000-0003-2757-1922
OpenAlex ID: A5012192522
First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients
2020 · Natalia V. Eremina, Vasily I. Kazey, et al. · Oncotarget · 14
PDF
A Case Report of Calyceal Diverticulum: Differential Diagnosis for Organ-Preserving Operations
2021 · Alexandr V. Kurkov, Viktoriya M. Pominalnaya, et al. · Frontiers in Surgery · 6
PDF
The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
2021 · А. А. Gritskevich, I. G. Rusakov, et al. · Meditsinskiy sovet = Medical Council · 4
Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer
2016 · B. Ya. Alekseev, V. B. Matveev, et al. · Cancer Urology · 4
PDF
A phase II study of 99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.
2014 · Kevin Mark Slawin, William J. Ellis, et al. · Journal of Clinical Oncology · 4
Efficacy and safety of cabozantinib in metastatic renal cell carcinoma patients: Russian multicenter observational study
2023 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 3
Atezolizumab (Tecentriq) as first-line therapy in patients with metastatic urothelial carcinoma
2022 · A. A. Gritskevich, T. P. Baitman, et al. · Meditsinskiy sovet = Medical Council · 3
PDF
Evaluation of Effect of Prolonged Action Somatostatin Analogue – Ocreotide-depo – on the Following Hormonal and Cytotoxic Therapy in Patients With Metastatic Castrate-resistant Prostate Cancer (м-crpc)
2017 · S. V. Mishugin, A. A. Gritskevich, et al. · Meditsinskiy sovet = Medical Council · 3
PDF
Some Specific Features of the Diagnosis and Treatment of Kidney Cancer in Russia: Preliminary Results of a Multicenter Cooperative Study
2014 · B. Ya. Alekseev, Yu. V. Anzhiganova, et al. · Oncourology (Russian Society of Oncourologists) · 3
PDF
The role of sunitinib in the therapy of metastatic renal cell carcinoma
2020 · I. G. Rusakov, A. A. Gritskevich, et al. · Meditsinskiy sovet = Medical Council · 2
PDF
Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM
2019 · M. I. Volkova, A. M. Abdelgafur, et al. · Cancer Urology · 2
PDF
Development and Clinical Effectiveness of Antiandrogens in the Treatment of Advanced Prostate Cancer
2016 · S. V. MISHUGIN, A. A. GRITSKEVICH, et al. · Meditsinskiy sovet = Medical Council · 2
PDF
Correlation of Technetium Tc99m trofolastat chloride (MIP-1404) uptake using SPECT/CT with histopathology: A phase 2 study of prostate cancer (PCa) patients undergoing radical prostatectomy (RP) with extended lymph node dissection (ePLND)
2014 · Gabriella Dabasi, Marinez Bizarro Barra, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
2023 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology · 1
PDF
Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
2022 · A. A. Gritskevich, A. Yu. Popov, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
2020 · I. G. Rusakov, A. A. Gritskevich, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
Study of the economic efficiency of the combined method of Octreotide-depo + dexamethasone therapy in the treatment of patients with castration-resistant prostate cancer
2019 · S. V. Mishugin, I. G. Rusakov, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
Metabolic disorders in case of androgen deprivation: the role of endocrinologist in the management of the case
2018 · T.Ju. Demidova Demidova, E.Ju. Gritzkevitch Gritzkevitch, et al. · Therapy · 1
Possibilities of a Combination of Docetaxel With Androgen Deprivation in Initial Therapy of Hormonesensitive Prostate Cancer
2017 · A. A. GRITSKEVICH, S. V. MISHUGIN, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
Stable castration level of testosterone in androgendeprivation therapy for clear cell renal cell carcinoma
2015 · A. A. Gritskevich, S. V. Mishugin, et al. · Malignant tumours · 1
Experience with abiraterone acetate in the treatment of metastatic prostate cancer
2015 · A. A. Gritskevich, S. V. Mishugin, et al. · P A Herzen Journal of Oncology · 1
Buserelin-long PhC in the treatment of disseminated prostate cancer
2015 · S. V. Mishugin, A. A. Mordovin, et al. · P A Herzen Journal of Oncology · 1
A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.
2014 · Kevin Mark Slawin, Peter Tenke, et al. · Journal of Clinical Oncology · 1
728 A phase 2 study of 99m TC-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) compared to histopathology: An interim analysis
2014 · P. Tenke, S. Joniau, et al. · European Urology Supplements · 1
The current abilities of third-generation luteinizing hormone-releasing hormone antagonists in the treatment of hormone-responsive prostate cancer
2014 · A. A. Gritskevich, V. L. Medvedev, et al. · P A Herzen Journal of Oncology · 1
Works count: 71
Citation count: 64
H-index: 4
I10-index: 1
Year
Topic
Type